US Nephrologists Embrace Current IgA Nephropathy Therapies, Yet a Thriving Pipeline Signals Fierce Market Evolution Ahead
According to Spherix Global Insights, US nephrologists have expressed a high level of enthusiasm for Novartis’ iptacopan and atrasentan, as...